# A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Source: https://onco.cc/trials/nct06203210/  
OnCo record `nct06203210` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in which amrubicin is one of the standard comparator treatments, run by Daiichi Sankyo in small-cell lung cancer, now recruiting.

## Summary

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06203210 by Daiichi Sankyo, with 540 participants planned, started 2024-05-21. Conditions listed: Small Cell Lung Cancer. Amrubicin is a comparator arm, not the drug under test. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06203210
- Phase: 3
- Setting: A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02)
- Sponsor: Daiichi Sankyo
- Enrolled: 540

## Sources

- ClinicalTrials.gov NCT06203210: https://clinicaltrials.gov/study/NCT06203210

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Amrubicin](https://onco.cc/drugs/amrubicin/)
- companies: [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/)

---
JSON: https://onco.cc/api/v1/entities/nct06203210.json